GeoVax Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

false 0000832489 0000832489 2024-10-15 2024-10-15 0000832489 govx:CommonStockParValue0001PerShareCustomMember 2024-10-15 2024-10-15 0000832489 govx:WarrantsToPurchaseCommonStockCustomMember 2024-10-15 2024-10-15

 

 

 

 

Date of report (Date of earliest event reported): October 15, 2024

 

 

 

 

 

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

On October 15, 2024, GeoVax Labs, Inc. (the “Company”) increased the maximum aggregate offering price of the shares issuable under its Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners, dated September 25, 2024, from $4,486,846 to $30,000,000. A copy of the legal opinion as to the legality of the shares issuable under the Sales Agreement is filed as Exhibit 5.1 attached hereto.

 

 

 

 

 

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.